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Abstract
Background: Prior literature has shown that racial/ethnic minorities with hypertension may
receive less aggressive treatment for their high blood pressure. However, to date there are few
data available regarding the confounders of racial/ethnic disparities in the intensity of hypertension
treatment.
Methods: We reviewed the medical records of 1,205 patients who had a minimum of two
hypertension-related outpatient visits to 12 general internal medicine clinics during 7/1/01-6/30/02.
Using logistic regression, we determined the odds of having therapy intensified by patient race/
ethnicity after adjustment for clinical characteristics.
Results: Blacks (81.9%) and Whites (80.3%) were more likely than Latinos (71.5%) to have therapy
intensified (P = 0.03). After adjustment for racial differences in the number of outpatient visits and
presence of diabetes, there were no racial differences in rates of intensification.
Conclusion:  We found that racial/ethnic differences in therapy intensification were largely
accounted for by differences in frequency of clinic visits and in the prevalence of diabetes. Given
the higher rates of diabetes and hypertension related mortality among Hispanics in the U.S., future
interventions to reduce disparities in cardiovascular outcomes should increase physician awareness
of the need to intensify drug therapy more agressively in patients without waiting for multiple clinic
visits, and should remind providers to treat hypertension more aggressively among diabetic
patients.
Background
Hypertension is among the most prevalent chronic dis-
eases in the United States [1]. Despite the availability of
effective medications and well-published guidelines for
the treatment of hypertension [1-4], the majority (approx-
imately 75%) of hypertension in the United States
remains poorly controlled [5].
Hypertension is particularly burdensome among racial/
ethnic minority groups and hypertension-related
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cardiovascular disease has been shown to be the greatest
contributor to previously documented racial differences
in mortality [5-12]. Although higher rates of hypertension
control and a reduction in racial differences in outcomes
from hypertension may be obtained by increasing provid-
ers' aggressiveness in intensifying therapy when indicated
[2,12], several studies have demonstrated that providers
often allow their patients to remain poorly controlled
[12,13].
We previously examined the association of patients' race/
ethnicity with processes of hypertension care [13]. We
found that, among a cohort of hypertension patients with
repeatedly elevated blood pressures, Hispanics were sig-
nificantly less likely to have therapy intensified and were
more likely to have uncontrolled blood pressure (BP)
than were other racial and ethnic groups. In an effort to
identify potential targets for interventions to improve
hypertension care among our patients, we further exam-
ined which patient and provider characteristics may
explain racial differences in rates of therapy
intensification.
Methods
Study sample and procedures
To determine which patient-centered characteristics are
associated with providers intensifying drug therapy for
hypertension and whether provider experience is related
to differences in intensification of therapy, we studied a
random subset of 1,205 patients who had a minimum of
two hypertension-related outpatient visits to one of
twelve general medicine clinics in community health cent-
ers and community practices affiliated with a large urban
academic medical center from July 1, 2001 through June
30, 2002 (totaling 3,257 visits). To determine hyperten-
sion-related visits, we reviewed the electronic medical
record (EMR) for all clinic visits with a primary or second-
ary diagnostic code of hypertension (HTN) (ICD-9 401-
401.9, 405- 405.99). The study protocol was approved by
the Human Studies Committee at the Brigham and
Women's Hospital.
Medical record and administrative data
We hired three abstractors who were trained by the pri-
mary investigator to review the EMR of each patient in our
study sample, each abstractor reviewed records for
approximately 400 individual patients. From each hyper-
tension-related visit note in the EMR they collected the
following data: patient race/ethnicity, name of the
patient's primary provider, patient age at time of initial
study period visit, sex, primary insurer at time of initial
study period visit, presence of comorbid disease (diabetes,
congestive heart failure (CHF), coronary artery disease
(CAD), or renal failure) listed on the patient problem list,
BP control (defined using cut point of <130/85 for dia-
betic or renal failure patients and <140/90 for all others),
and any changes made to antihypertensive drug therapy
during visit (decrease or discontinuation of drug, change
to another class of drug, or increase of drug dose or addi-
tion of new drug).
The EMR of each patient contains racial/ethnic data
obtained via self-report the first time each patient registers
in his/her clinic that then is classified by the data entry
clerk as Hispanic ethnicity or not and race is then classi-
fied as Black, White, other, or unknown. Hence, it is
impossible to know the country of origin of our Hispanic
participants and we could not determine the exact racial/
ethnic mix of patients classified as "other" or "unknown."
For these reasons, we excluded patients who's EMR listed
their racial/ethnic classification as "other" (N = 25) or
"unknown" (N = 67) and we limited our analyses to
White patients (who identify themselves as non-His-
panic), Black patients (who identify themselves as non-
Hispanic), and self-identified Hispanic patients.
From the medical center's administrative database, we
abstracted each provider's level of experience (intern, res-
ident, or attending). Patient zip code was also obtained
and linked to 2000 U.S. Census data to obtain the median
annual household income in each patient's zip code.
Intensity of therapy
Our methods for identifying intensified cases among our
cohort have been previously described [13]. Because we
were examining the quality of care delivered to hyperten-
sion patients prior to July of 2002, approximately one year
before the release of the Seventh Report of the Joint
National Committee on Prevention, Detection, Evalua-
tion and Treatment of High Blood Pressure (JNC VII) [14],
we used JNC VI definitions for blood pressure control in
order to examine whether therapy was appropriately
intensified. We classified each visit into two categories,
intensified visits (an increase in intensity of drug therapy)
versus non-intensified visits (a decrease or no change in
intensity of drug therapy) according to previously pub-
lished definitions of changes in medications [2]. We
developed an algorithm to determine whether a patient
received at least one increase in drug therapy (an increase
in drug dose or addition of new medication) in response
to a repeatedly elevated BP during the study period (Fig-
ure 1). Each patient with fewer than two visits with an ele-
vated BP (N = 356) was excluded from the algorithm.
Each patient with an uncontrolled BP at more than one
visit was identified as either an intensified case (at least
one drug increase) or a non-intensified case (no drug
increases). Each reviewer examined a subset of 30 records;
we then tested for inter-rater reliability and found excel-
lent agreement among reviewers (kappa = 0.90).BMC Cardiovascular Disorders 2005, 5:16 http://www.biomedcentral.com/1471-2261/5/16
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Flow diagram of algorithm for determining an "intensified case Figure 1
Flow diagram of algorithm for determining an "intensified case." Inter-rater reliability was high (kappa 0.90). We identified a 
total of 782 cases as either an "intensified case (N = 600) or a "non-intensified case" (N = 157).
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Our intensification algorithm is potentially limited
because it does not account for differences in the number
of times medication is increased in comparison to the
number of uncontrolled BP visits for each patient. To
address this issue, we created a secondary measure of
intensification by calculating the proportion of times each
patient had their therapy increased when their BP was
uncontrolled (0 representing no increases and 1 repre-
senting an increase in therapy with every uncontrolled
visit). We then determined whether the two intensifica-
tion measures were correlated in order to further validate
our algorithm and found that the two measures were
highly correlated (coefficient 0.71, P <0.001). Because our
algorithm-derived method has the additional advantage
of using more than a single visit's BP in determining
whether therapy intensification is indicated, we used this
measure of intensification for all subsequent analyses.
Data analysis
We compared patients' demographic, clinical, and pro-
vider's characteristics by patient race/ethnicity (Table 1)
using chi-squared tests for categorical and Student's t-test
for continuous variables. We also estimated the associa-
tion of being an intensified case with patients' demo-
graphic, clinical, and provider's characteristics (Table 2).
We report two-tailed P values with statistical significance
set at P≤ 0.05 for all analyses.
Using logistic regression, we assessed whether race/ethnic-
ity was associated with intensification of therapy after
adjusting for all measured confounders. Data were availa-
ble on every variable for 685 of the 757 patients (90.5%)
for multivariable analyses. We report adjusted odds ratios
with 95% confidence intervals for the intensified cases. In
secondary analyses, we included interaction terms for
patient race/ethnicity and provider experience level to
determine whether racial/ethnic differences in intensifica-
tion differed by provider experience level. All non-signifi-
cant interaction terms were removed from the final
model. All models were estimated using SUDAAN
statistical software to adjust for within clinic correlation of
visits [15].
Results
Patient, clinical, and provider characteristics
Of the 757 patients, 304 (40%) were White, 309 (41%)
were Black, and 144 (19%) were Hispanic (Table 1). The
majority of patients in our cohort were women (72%) and
most were either privately insured or had Medicare
(71%). There were 169 (22%) patients in our cohort with
diabetes. We were able to determine the primary provider
for 691 patients, of who 44 (6.4%) received care from an
intern, 89 (12.9%) received care from a resident, and 558
(80.8%) received care from an attending. Demographic
and clinical differences between patients' racial/ethnic
groups are presented in Table 1.
Table 1: Demographic and clinical characteristics of population by race and ethnicity
Variable White (N = 304) Black (N = 309) Hispanic (N = 144) P value*
Men (%) 27.3 24.3 35.4 0.05
Aged <65 years (%) 54.6 65.1 66.7 0.009
Annual household income†: <0.001
= $35,500 11.9 37.8 29.4
$35,501–$43,140 11.9 40.8 21.0
$43,141–$55,365 24.7 15.5 42.7
> $55,365 51.6 5.9 7.0
Insurance: <0.001
Private/Medicare (%) 87.7 69.1 40.3
Medicaid (%) 4.3 17.6 28.5
Free care/Self-pay (%) 8.0 13.4 31.3
Mean number of 
hypertension visits
2.8 3.0 2.8 0.06
Diabetic (%) 14.5 27.5 27.8 <0.001
Coronary artery disease 
(%)
5.3 4.2 2.1 0.02
Provider experience (%)‡: <0.001
Intern 2.1 9.3 10.1
Resident 4.8 23.0 10.1
Attending 93.2 67.8 79.8
*Using chi-square tests for categorical variables and ANOVA for mean number of hypertension visits.
†N = 734 for those patients with zip code available.
‡N = 691 for those patients with provider information available.BMC Cardiovascular Disorders 2005, 5:16 http://www.biomedcentral.com/1471-2261/5/16
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Intensification of therapy
Of the 757 patients with multiple visits whose BP was
uncontrolled at two or more visits, there were 600
(79.3%) who had their medications intensified. Hispanic
patients were significantly less likely to have their medica-
tions intensified than White and Black patients (Table 2).
Diabetic patients and those with fewer visits during the
study period were also less likely to have their medica-
tions intensified.
After adjustment for age, insurance status, number of
hypertension-related visits, diabetes, and physician expe-
rience, there were no remaining racial/ethnic differences
in rates of intensification (Table 3). Compared to patients
aged = 65 years, younger patients were more likely to have
their therapy intensified, and the odds of having therapy
intensified increased with each visit. There were no
significant interactions between race/ethnicity and pro-
vider experience in the multivariable model.
Discussion
In our prior work, we found that Hispanic patients were
more likely to receive the JNC recommended antihyper-
tensive drug class then Whites, however, Hispanics were
also significantly less likely than Whites to have their ther-
apy appropriately intensified in response to an uncon-
trolled BP [13]. Furthermore, we found appropriate
intensification of anti-hypertensive therapy was associ-
ated with subsequent BP control for all racial/ethnic
groups, suggesting that the poorer rates of BP control
among Hispanics in our prior study may have been due to
significantly lower rates of antihypertensive medication
intensification [13]. In this study, we found that these pre-
viously noted racial/ethnic disparities in rates of antihy-
pertensive therapy intensification may be due to
differences in visit patterns among patients and in physi-
cians' aggressiveness in managing BP in diabetic patients,
suggesting that racial/ethnic differences in disease severity
are likely determinants of unequal treatment of uncon-
trolled hypertension.
Table 2: Demographic and clinical characteristics of population by intensification of therapy
Variable Non-Intensified Case (N = 157) Intensified Case (N = 600) P value*
Patient race/ethnicity (%): 0.03
White 19.7 80.3
Black 18.1 81.9
Hispanic 28.5 71.5
Men (%) 29.1 27.7 0.74
Age: 0.10
<65 years 18.8 81.2
≥ 65 years 23.8 76.2
Annual household income†: 0.93
≤ $35,500 20.4 79.6
$35,501–$43,140 19.7 80.3
$43,141–$55,365 22.4 77.6
> $55,365 20.5 79.5
Insurance: 0.15
Private/Medicare (%) 19.5 80.5
Medicaid (%) 27.8 72.2
Free care/Self-pay (%) 20.0 80.0
Mean number of hypertension visits 2.6 3.0 <0.001
Diabetic (%): 0.01
Yes 27.8 72.2
No 18.7 81.3
Coronary artery disease (%): 0.24
Yes 12.5 87.5
No 21.1 78.9
Provider training level (%)‡: 0.91
Intern 22.7 77.3
Resident 21.4 78.6
Attending 20.3 79.7
*Using chi-square tests for categorical variables and Student's t-test to compare mean hypertension visits.
†N = 734 for those patients with zip code available.
‡N = 691 for those patients with provider information available.BMC Cardiovascular Disorders 2005, 5:16 http://www.biomedcentral.com/1471-2261/5/16
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There is substantial literature, that suggests that racial/eth-
nic minority groups are less likely to have their antihyper-
tensive therapy appropriately intensified [16-19].
However, these studies were limited because the investiga-
tors were not able to assess practice patterns such as the
frequency with which individual anti-hypertensive drugs
were intensified in response to uncontrolled BP. We
found that Hispanic patients in our cohort were also less
likely to have their anti-hypertensive medications intensi-
fied at least once in response to repeatedly uncontrolled
BP than were other racial/ethnic groups and our findings
also expand beyond documenting racial/ethnic disparities
in aggressiveness of therapy by determining the roles
racial/ethnic differences in clinic utilization among
patients and racial/ethnic differences in the prevalence of
diabetes play in confounding differences in providers'
aggressiveness in treating hypertension.
An important national priority in health care is the elimi-
nation of racial/ethnic disparities in healthcare; however,
a better understanding of the determinants of disparities
is needed to address this issue [20,21]. Our finding that
higher rates of diabetes among Hispanics in our cohort
play a major role in the insufficient management of their
uncontrolled BP is of particular concern given that His-
panics suffer a disproportionately larger burden from
hypertension and diabetes compared to Whites; and that
Hispanics are at a higher risk of having hypertension and
diabetes, are less likely to be aware that they are hyperten-
sive, are more likely to have target organ damage, and
have significantly higher age-adjusted diabetes and hyper-
tension-related mortality compared to whites in the U.S
[5,6,22,23]. Our findings are supported by several studies
that have documented lower rates of BP control among
diabetic patients [24,25], and others showing that provid-
ers often do not attain adequate BP control for patients,
even after multiple opportunities to do so [2,24].
Our study has several limitations. We were unable to col-
lect measures of patient adherence to prescribed therapy
from the EMR. Providers may not want to intensify ther-
apy at the same rate for patients they know are less com-
pliant with therapy, although it is hard to identify these
patients. We were also unable to determine English profi-
ciency of each patient from the medical records. When a
language barrier exists providers may be less likely to
intensify therapy.
We examined disparities in quality of hypertension care,
as measured by intensification of therapy, among a cohort
of patients and physicians during 2001–2002 using the
established guidelines available during that time period,
the JNC VI, as the reference for our analyses. In
comparison to JNC VI, the JNC VII guidelines recommend
much more aggressive management of hypertension both
in terms of the accepted level of BP control (130/80 for
diabetic and renal failure patients and 140/90 for all oth-
ers) and the recommendations to providers to intensify
antihypertensive therapy more rapidly when BP is uncon-
trolled [14]. However, since the JNC VII guidelines were
not available until 2003, it would have been impossible
for providers in our study sample to have been fully aware
of them and it would have been misleading to assess the
quality of hypertension care among our cohort using
quality guidelines that were not in existence during that
time. By using the less aggressive guidelines that were in
existence during the study period, we may have underesti-
mated the gap in rates of intensification between racial/
Table 3: Adjusted odds ratios* [95% C.I.] of being an intensified case
Variable Odds Ratios of being Intensified Case 95 % Confidence interval
Black† 1.09 [0.71–1.67]
Hispanic† 0.78 [0.58–1.06]
Age < 65 years‡ 1.61 [1.38–1.88]
Medicaid§ 0.76 [0.57–1.02]
Free care or self pay§ 1.22 [0.73–2.03]
Number of hypertension visits|| 1.37 [1.17–1.61]
Diabetes** 0.61 [0.34–1.08]
Intern provider†† 0.86 [0.39–1.88]
Resident provider†† 0.89 [0.55–1.46]
* Adjusted for patient race/ethnicity, age, insurance status, number of hypertension-related visits, diabetes, and physician experience.
†Whites use as reference group
‡Aged ≥  65 years used as reference group
§Privately insured or Medicare used as reference group
||Represents increase in odds with each additional visit
**No diabetes used as reference group
††Attending provider used as reference groupBMC Cardiovascular Disorders 2005, 5:16 http://www.biomedcentral.com/1471-2261/5/16
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ethnic groups and between patients with diabetes and
those without.
Lastly, we examined patients who received their care at
primary care practices affiliated with a single large urban
teaching hospital, and although there was substantial
socioeconomic diversity in our sample our results may
not be generalizable to smaller, rural, or non-teaching
hospitals.
Conclusion
We found significant racial/ethnic differences in intensifi-
cation of drug therapy, and that these differences were
largely accounted for by differences in frequency of clinic
visits and in the prevalence of diabetes. Future interven-
tions should focus on increasing physician awareness of
the need to intensify drug therapy more, particulary
among Hispanic patients, and on encouraging providers
to treat hypertension more intensively in diabetic
patients.
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